New England Research & Management’s Anika Therapeutics ANIK Stock Holding History

New England Research & Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-4,200	Closed	-$209K	–	168
2018 Q1	$209K	Buy	+4,200	New	+$237K	0.14%	151
2017 Q3	–	Sell	-8,795	Closed	-$434K	–	156
2017 Q2	$434K	Sell	8,795 -1,500	-15%	-$69.1K	0.32%	101
2017 Q1	$447K	Buy	+10,295	New	+$491K	0.34%	96

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

New England Research & Management's ANIK Position: Q2 2018 in Review

New England Research & Management sold out of Anika Therapeutics (ANIK) in Q2 2018, closing a stake of 4,200 shares — an estimated $209K sold.

New England Research & Management first reported a position in ANIK in Q1 2017 and held it in 3 quarters. The position peaked at $447K in Q1 2017. 170 funds tracked by Wall St. Rank hold ANIK as of Q2 2018.

New England Research & Management reported no remaining Anika Therapeutics position as of Q2 2018 after selling out during the quarter.
New England Research & Management sold 4,200 Anika Therapeutics shares in Q2 2018, an estimated $209K.
New England Research & Management first reported a position in Anika Therapeutics in Q1 2017 and held it in 3 quarters.
New England Research & Management's Anika Therapeutics position peaked at $447K in Q1 2017.
170 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2018.

Based on New England Research & Management's 13F filing for Q2 2018, filed 5 Jul 2018.